Greenwich LifeSciences, Inc. (GLSI)
Fuera de horario:
Greenwich LifeSciences, Inc.
Building 14
3992 Bluebonnet Drive
Stafford, TX 77477
United States
832 819 3232
https://greenwichlifesciences.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 3
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Snehal S. Patel | CEO, CFO & Director | 1.09M | N/D | 1964 |
| Mr. Eric Rothe | Founder & Independent Director | 65.64k | N/D | 1976 |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | N/D | N/D | 1951 |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs | N/D | N/D | 1966 |
| Dr. Christine T. Fischette Ph.D. | VP of Business Development | N/D | N/D | 1951 |
Descripción
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Greenwich LifeSciences, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
